| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
3DR® Labs to Offer Nanox.AI's FDA-Cleared Imaging Solutions to Its Network of More Than 1,800 Hospitals and Imaging Centers Across the U.S.
PETACH TIKVA, Israel, Nov. 18, 2025 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (("Nanox" or the "Company", NASDAQ:NNOX), an innovative medical imaging technology company, today announced a strategic reseller partnership with 3DR Labs, LLC, one of the largest providers of medical image post-processing services in the United States. Through this collaboration, 3DR Labs will offer Nanox.AI's FDA-cleared solutions to its network of more than 1,800 hospitals, diagnostic imaging centers, and healthcare providers.
Under the terms of the collaboration, 3DR Labs will integrate Nanox.AI's advanced, FDA-cleared software solutions, HealthCCSng (AI cardiac solution), HealthOST (AI bone solution), and HealthFLD (AI liver solution), into its imaging services portfolio, making these AI-powered tools available to healthcare providers across its nationwide network.
The partnership enables 3DR Labs to market, distribute Nanox.AI's software solutions to its client base across North America. The agreement positions Nanox.AI's technology to support early signs of disease detection and improve clinical outcomes management initiatives at scale across one of the largest medical imaging service networks in the United States.
Nanox entered into a commercial agreement with 3DR, whose CEO also serves as a director at Nanox. The agreement was approved in accordance with the law applicable to related-party transactions.
Posted In: NNOX
